Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555733 |
JP |
7 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, |
||||
| 2 | 26555868 |
8 | 2 | |
Diffuse large B-cell lymphoma refractory, Malignant neoplasm progression, |
||||
EPCORITAMAB-BYSP, |
||||
| 3 | 26556540 |
JP |
8 | 2 |
Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, |
||||
| 4 | 26556741 |
US |
70 | 1 |
Malignant neoplasm progression, |
||||
RIPRETINIB, |
||||
| 5 | 26556963 |
CA |
71 | 1 |
Malignant neoplasm progression, |
||||
BORTEZOMIB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 6 | 26557188 |
CA |
60 | 1 |
Malignant neoplasm progression, |
||||
BORTEZOMIB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 7 | 26557260 |
JP |
46 | 2 |
Death, Malaise, Hypertension, Palmar-plantar erythrodysaesthesia syndrome, Therapy partial responder, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 8 | 26557722 |
US |
35 | 2 |
Solid organ transplant rejection, Sepsis, Acute kidney injury, Malignant neoplasm progression, |
||||
CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, PEMBROLIZUMAB, |
||||
| 9 | 26557877 |
JP |
7 | 2 |
Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 10 | 26557916 |
EU |
66 | 2 |
Death, Breast cancer, Malignant neoplasm progression, Lung disorder, Metastases to bone, Pleural effusion, Pleural disorder, Disease progression, Computerised tomogram abnormal, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 11 | 26558906 |
JP |
7 | 2 |
Malignant neoplasm progression, |
||||
ZONGERTINIB, |
||||
| 12 | 26558907 |
GB |
2 | |
Malignant neoplasm progression, |
||||
NINTEDANIB, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 13 | 26559291 |
CN |
14 | |
Acute lymphocytic leukaemia recurrent, Malignant neoplasm progression, Off label use, |
||||
RUXOLITINIB, TRAMETINIB, INOTUZUMAB OZOGAMICIN, VENETOCLAX, VENETOCLAX, VENETOCLAX, |
||||
| 14 | 26559438 |
50 | ||
Respiratory disorder, Cardiotoxicity, Angina pectoris, Orbital space occupying lesion, Neuropathy peripheral, Malignant neoplasm progression, Photopsia, |
||||
GEMCITABINE HYDROCHLORIDE, CAPECITABINE, SACITUZUMAB GOVITECAN, VINORELBINE, |
||||
| 15 | 26559475 |
CA |
44 | 2 |
Malignant neoplasm progression, Fungal skin infection, Contusion, Fatigue, Diarrhoea, Blood pressure increased, Laryngitis, Chest pain, Malaise, Off label use, Vomiting, Diarrhoea, Gastroenteritis viral, Dehydration, Off label use, |
||||
LANREOTIDE ACETATE, CABOZANTINIB, CABOZANTINIB, |
||||
| 16 | 26560041 |
GB |
2 | |
Malignant neoplasm progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, NINTEDANIB, |
||||
| 17 | 26560311 |
EU |
1 | |
Oesophageal stenosis, Metastases to oesophagus, Thyroid cancer, Malignant neoplasm progression, Dysphagia, Wrong technique in product usage process, |
||||
TRAMETINIB, DABRAFENIB, |
||||
| 18 | 26560668 |
JP |
||
Osteomyelitis, Malignant neoplasm progression, |
||||
NIVOLUMAB, OXALIPLATIN, |
||||
| 19 | 26560670 |
EU |
72 | 2 |
Malignant neoplasm progression, Toxic skin eruption, Acquired epidermolysis bullosa, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, DOSTARLIMAB, |
||||
| 20 | 26561122 |
EU |
67 | 2 |
Tumour pseudoprogression, Compartment syndrome, Malignant neoplasm progression, Haematotoxicity, |
||||
IDECABTAGENE VICLEUCEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUDARABINE PHOSPHATE, |
||||
| 21 | 26561538 |
JP |
87 | 1 |
Malignant neoplasm progression, Adverse reaction, Pre-existing disease, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 22 | 26561578 |
EU |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, GEFITINIB, GEFITINIB, |
||||
| 23 | 26565897 |
70 | 1 | |
Malignant neoplasm progression, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 24 | 26550119 |
JP |
8 | 1 |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 25 | 26550225 |
CA |
2 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 26 | 26550564 |
EU |
62 | 1 |
Immune-mediated lung disease, Malignant neoplasm progression, |
||||
CISPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 27 | 26550669 |
US |
55 | 1 |
Cardiac disorder, Malignant neoplasm progression, Glossodynia, Dizziness, Diarrhoea, Stomatitis, Oral pain, Decreased appetite, Constipation, Nausea, Vomiting, Asthenia, Weight decreased, Abdominal pain, Decreased activity, Odynophagia, Abdominal mass, Abdominal distension, |
||||
NIVOLUMAB, CABOZANTINIB, |
||||
| 28 | 26550807 |
CH |
65 | 2 |
Multiple organ dysfunction syndrome, Malignant neoplasm progression, Immune-mediated hepatitis, Immune thrombocytopenia, Polyserositis, Immune-mediated thyroiditis, |
||||
NIVOLUMAB, IPILIMUMAB, |
||||
| 29 | 26550961 |
EU |
78 | 1 |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 30 | 26550983 |
JP |
2 | |
Malignant neoplasm progression, Decreased appetite, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 31 | 26551338 |
EU |
75 | 2 |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 32 | 26551504 |
CA |
58 | 2 |
Metastases to gastrointestinal tract, Off label use, Triple negative breast cancer, Metastases to liver, Malignant neoplasm progression, |
||||
CARBOPLATIN, GEMCITABINE HYDROCHLORIDE, PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), SACITUZUMAB GOVITECAN, |
||||
| 33 | 26551676 |
JP |
7 | 2 |
Malignant neoplasm progression, |
||||
ZOLBETUXIMAB, |
||||
| 34 | 26551885 |
JP |
9 | 1 |
Malignant neoplasm progression, Ill-defined disorder, Immune-mediated enterocolitis, Gastroenteritis, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMETREXED DISODIUM, PEMETREXED DISODIUM, |
||||
| 35 | 26551947 |
63 | 2 | |
Hepatic cancer, Malignant neoplasm progression, Back pain, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 36 | 26551999 |
JP |
8 | |
Neuroendocrine tumour, Malignant neoplasm progression, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 37 | 26552603 |
CN |
57 | 2 |
Malignant neoplasm progression, Ecchymosis, Dyspnoea, Arthralgia, Chest discomfort, Sensory disturbance, Antibody test positive, Lymphadenopathy, Feeling abnormal, |
||||
OSIMERTINIB, OSIMERTINIB, |
||||
| 38 | 26553182 |
EU |
67 | 1 |
Malignant neoplasm progression, Off label use, Incorrect dosage administered, Benign prostatic hyperplasia, Haemoglobin abnormal, Vocal cord paralysis, Ascites, |
||||
BEVACIZUMAB, OLAPARIB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CABOZANTINIB, LENVATINIB, |
||||
| 39 | 26553260 |
US |
72 | 2 |
Respiratory syncytial virus infection, Fall, Craniofacial fracture, Haemorrhage, Malignant neoplasm progression, Pulmonary mass, Pancreatic cyst, Nail growth abnormal, Face injury, Post procedural complication, Dysphonia, Musculoskeletal stiffness, Back pain, Musculoskeletal pain, Pain in extremity, Vertigo, Chest discomfort, Weight increased, Fall, Asthma, Hot flush, Breast calcifications, Hair colour changes, Tongue discomfort, Scar, Increased tendency to bruise, Erythema, Dyspnoea, Cough, Fatigue, Diarrhoea, Decreased appetite, Nausea, Alopecia, |
||||
ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, ANASTROZOLE, ANASTROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, GABAPENTIN, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, GUAIFENESIN, GUAIFENESIN, TEZEPELUMAB-EKKO, HELIANTHEMUM NUMMULARIUM FLOWER, CLEMATIS VITALBA FLOWER, IMPATIENS GLANDULIFERA FLOWER, PRUNUS CERASIFERA FLOWER, ORNITHOGALUM UMBELLATUM, AND MALUS DOMESTICA FLOWER, CLEMATIS VITALBA FLOS, HELIANTHEMUM NUMMULARIUM FLOS, IMPATIENS GLANDULIFERA FLOS, ORNITHOGALUM UMBELLATUM FLOS, PRUNUS CERASIFERA FLOS, BIOTIN, IRON, ERGOCALCIFEROL, AZACITIDINE, |
||||
| 40 | 26553896 |
CA |
2 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, AMIVANTAMAB-VMJW, |
||||
| 41 | 26553926 |
TW |
51 | 2 |
Malignant neoplasm progression, Headache, |
||||
AFATINIB, AFATINIB, |
||||
| 42 | 26553937 |
EU |
79 | 2 |
Neutropenia, Malignant neoplasm progression, Acute myeloid leukaemia, COVID-19, |
||||
AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, VENETOCLAX, VENETOCLAX, |
||||
| 43 | 26553947 |
US |
||
Malignant neoplasm progression, |
||||
IMLUNESTRANT, |
||||
| 44 | 26553969 |
JP |
75 | 2 |
Malignant neoplasm progression, Bile duct stone, Drug-induced liver injury, Hypertension, Diarrhoea, Malaise, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, LENVATINIB, |
||||
| 45 | 26554485 |
ZA |
57 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Metastases to liver, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 46 | 26554556 |
EU |
3 | 2 |
Sarcoma, Malignant neoplasm progression, Off label use, Off label use, |
||||
CARBOPLATIN, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 47 | 26554574 |
IL |
60 | 1 |
Malignant neoplasm progression, |
||||
PIRTOBRUTINIB, |
||||
| 48 | 26555034 |
VN |
71 | 2 |
Gastrointestinal wall thickening, Malignant neoplasm progression, Female genital tract fistula, Proctitis ulcerative, Proctitis haemorrhagic, |
||||
PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, BEVACIZUMAB, |
||||
| 49 | 26555213 |
JP |
8 | 1 |
Malignant neoplasm progression, Oedema, Epilepsy, |
||||
BELZUTIFAN, CABOZANTINIB, |
||||
| 50 | 26569148 |
17 | 1 | |
Malignant neoplasm progression, Anaphylactic reaction, |
||||
CARBOPLATIN, ETOPOSIDE, FILGRASTIM, IFOSFAMIDE, MESNA, MESNA INJECTION, PEGFILGRASTIM, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 51 | 26549814 |
JP |
7 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 52 | 26549829 |
JP |
8 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 53 | 26547746 |
EU |
58 | 2 |
Malignant neoplasm progression, Fluid retention, Lymphoedema, Oedema, Therapy partial responder, Radiotherapy, Asthenia, Fatigue, Bone pain, Cough, Hypochromic anaemia, Oedema peripheral, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, |
||||
| 54 | 26542135 |
US |
69 | 1 |
Malignant neoplasm progression, |
||||
NIVOLUMAB AND HYALURONIDASE-NVHY, |
||||
| 55 | 26542149 |
EU |
44 | |
Malignant neoplasm progression, Triple negative breast cancer, |
||||
BEVACIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 56 | 26542646 |
JP |
7 | 2 |
Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 57 | 26542802 |
JP |
8 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, |
||||
| 58 | 26542836 |
EU |
61 | 1 |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 59 | 26542883 |
SG |
39 | 2 |
Malignant neoplasm progression, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 60 | 26542903 |
EU |
40 | 1 |
Cardiomyopathy, Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 61 | 26542981 |
79 | 2 | |
Malignant neoplasm progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 62 | 26543162 |
JP |
6 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 63 | 26543233 |
US |
70 | 1 |
Malignant neoplasm progression, Blood urine present, Condition aggravated, Urinary bladder haemorrhage, Urinary retention, Feeling abnormal, |
||||
ENZALUTAMIDE, MOMELOTINIB, |
||||
| 64 | 26544066 |
TR |
2 | |
Malignant neoplasm progression, |
||||
CAPECITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), METHOTREXATE, METHOTREXATE SODIUM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 65 | 26544585 |
KR |
38 | |
Malignant neoplasm progression, |
||||
GOSERELIN, GOSERELIN, |
||||
| 66 | 26544756 |
EU |
53 | 2 |
Neutropenia, Neutropenia, Neutropenia, Ascites, Malignant neoplasm progression, Product use issue, Tumour marker increased, |
||||
TRIFLURIDINE AND TIPIRACIL, BEVACIZUMAB, |
||||
| 67 | 26544784 |
CA |
69 | 2 |
Condition aggravated, Body temperature decreased, Diarrhoea, Fatigue, Lacrimation increased, Malignant neoplasm progression, Neuropathy peripheral, Off label use, Oxygen saturation decreased, Palmar-plantar erythrodysaesthesia syndrome, Paraesthesia, Sciatica, Transitional cell carcinoma metastatic, Vision blurred, Vomiting, Back pain, |
||||
PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, |
||||
| 68 | 26545069 |
IN |
1 | |
Feeding disorder, Abdominal discomfort, Malignant neoplasm progression, |
||||
DURVALUMAB, |
||||
| 69 | 26545104 |
US |
67 | 2 |
Malignant neoplasm progression, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, |
||||
| 70 | 26545122 |
JP |
7 | 1 |
Malignant neoplasm progression, Product dose omission in error, |
||||
BELZUTIFAN, |
||||
| 71 | 26545142 |
GB |
2 | |
Ophthalmic herpes zoster, Malignant neoplasm progression, Erythema nodosum, Pyrexia, Malaise, Gastrooesophageal reflux disease, |
||||
OLAPARIB, OLAPARIB, |
||||
| 72 | 26545160 |
JP |
8 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, BELZUTIFAN, LENVATINIB, |
||||
| 73 | 26545177 |
US |
64 | 2 |
Malignant neoplasm progression, Gastrooesophageal reflux disease, Melanocytic naevus, |
||||
RIPRETINIB, NITROFURANTOIN, NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), |
||||
| 74 | 26545214 |
EU |
68 | 2 |
Polyneuropathy, Malignant neoplasm progression, Thrombocytopenia, |
||||
RAMUCIRUMAB, RAMUCIRUMAB, DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DURVALUMAB, DURVALUMAB, |
||||
| 75 | 26545533 |
EU |
62 | 1 |
Pericardial effusion, Malignant neoplasm progression, Pleural effusion, |
||||
PEMETREXED DISODIUM, PEMETREXED DISODIUM, PEMETREXED DISODIUM, NIVOLUMAB, NIVOLUMAB, CARBOPLATIN, CARBOPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, TAMSULOSIN HYDROCHLORIDE, CANDESARTAN CILEXETIL, APREPITANT, FOSAPREPITANT DIMEGLUMINE, METOCLOPRAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 76 | 26545773 |
EU |
84 | 1 |
Transitional cell carcinoma urethra, Malignant neoplasm progression, Respiratory failure, Toxic epidermal necrolysis, Condition aggravated, |
||||
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 77 | 26545948 |
TH |
71 | 1 |
Pyrexia, Sepsis, Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
| 78 | 26545949 |
IN |
57 | 2 |
Malignant gastrointestinal obstruction, Malignant neoplasm progression, Feeding disorder, Vomiting, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
| 79 | 26546084 |
US |
1 | |
Loss of consciousness, Malignant neoplasm progression, Hypotension, Dehydration, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 80 | 26546122 |
EU |
42 | 2 |
Pathological fracture, Malignant neoplasm progression, Drug resistance, |
||||
PEMBROLIZUMAB, CAPECITABINE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, RIBOCICLIB, |
||||
| 81 | 26546281 |
IN |
2 | |
Death, Malignant neoplasm progression, Therapy non-responder, |
||||
PEMBROLIZUMAB, |
||||
| 82 | 26546700 |
US |
29 | 1 |
Malignant neoplasm progression, Noninfective encephalitis, Brain oedema, Head discomfort, Pain in extremity, Anxiety, Chest pain, |
||||
VORASIDENIB, |
||||
| 83 | 26552014 |
2 | ||
Malignant neoplasm progression, |
||||
ALPELISIB, |
||||
| 84 | 26536098 |
GB |
86 | 2 |
Death, Wrong technique in product usage process, Nausea, Constipation, Fatigue, Malignant neoplasm progression, Product use complaint, |
||||
LANSOPRAZOLE, ELACESTRANT, ELACESTRANT, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, |
||||
| 85 | 26536109 |
EU |
1 | |
Malignant neoplasm progression, Hormone receptor positive HER2 negative breast cancer, |
||||
FULVESTRANT, PALBOCICLIB, |
||||
| 86 | 26536279 |
JP |
8 | 1 |
Death, Chest pain, Perforation, Malignant neoplasm progression, White blood cell count increased, C-reactive protein increased, |
||||
PEMBROLIZUMAB, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 87 | 26536437 |
EU |
1 | |
Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 88 | 26536465 |
TR |
64 | 1 |
Malignant neoplasm progression, Prostatic specific antigen increased, |
||||
ENZALUTAMIDE, GOSERELIN, |
||||
| 89 | 26536489 |
JP |
1 | |
Malignant neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, Proteinuria, |
||||
BELZUTIFAN, PEMBROLIZUMAB, |
||||
| 90 | 26536547 |
JP |
68 | 2 |
Death, Hypothyroidism, Malignant neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 91 | 26537187 |
TW |
81 | 1 |
Immune-mediated hepatitis, Metastases to lung, Malignant neoplasm progression, Alpha 1 foetoprotein increased, Protein induced by vitamin K absence or antagonist II increased, |
||||
DURVALUMAB, |
||||
| 92 | 26537525 |
CA |
||
Oesophageal adenocarcinoma, Malignant neoplasm progression, Intentional product use issue, |
||||
TRASTUZUMAB, |
||||
| 93 | 26537774 |
GB |
86 | 2 |
Death, Malignant neoplasm progression, Fatigue, Nausea, Constipation, Product use complaint, Wrong technique in product usage process, |
||||
ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ELACESTRANT, ELACESTRANT, LANSOPRAZOLE, |
||||
| 94 | 26537885 |
EU |
42 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
OLAPARIB, |
||||
| 95 | 26538129 |
CN |
14 | 1 |
Acute lymphocytic leukaemia recurrent, Malignant neoplasm progression, Off label use, |
||||
TRAMETINIB, RUXOLITINIB, INOTUZUMAB OZOGAMICIN, VENETOCLAX, VENETOCLAX, VENETOCLAX, |
||||
| 96 | 26538407 |
US |
68 | 1 |
Malignant neoplasm progression, Neuropathy peripheral, Vocal cord paralysis, Haemoptysis, General physical condition abnormal, White blood cell count increased, Decreased appetite, Blood alkaline phosphatase increased, Blood sodium decreased, Blood chloride decreased, Fatigue, Dysphonia, Cough, Arthralgia, Myalgia, Weight decreased, Haemoglobin decreased, Haematocrit decreased, Blood glucose increased, Seborrhoeic dermatitis, Pruritus, Normocytic anaemia, Hypertension, Oedema, Off label use, Drug intolerance, Oedema peripheral, Erythema, Confusional state, Dysphonia, Respiratory disorder, Gastrooesophageal reflux disease, Nausea, Vomiting, Hypoglycaemia, Visual impairment, Dyspnoea, Dyspnoea, |
||||
OLAPARIB, OLAPARIB, NICOTINE POLACRILEX, |
||||
| 97 | 26538446 |
EU |
2 | |
Malignant neoplasm progression, Renal failure, |
||||
PEMBROLIZUMAB, |
||||
| 98 | 26538536 |
EU |
2 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, OSIMERTINIB, |
||||
| 99 | 26538600 |
JP |
9 | 1 |
Death, Malignant neoplasm progression, Fluid intake reduced, |
||||
TOLVAPTAN, TOLVAPTAN, |
||||
| 100 | 26538657 |
EU |
33 | |
Intermenstrual bleeding, Malignant neoplasm progression, Cough, Neutropenia, |
||||
BEVACIZUMAB, TRIFLURIDINE AND TIPIRACIL, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28